Literature DB >> 10396610

Cholesterol in peripheral vascular disease--a suitable case for treatment?

A L Clark1, J C Byrne, A Nasser, E McGroarty, J A Kennedy.   

Abstract

We assessed the prevalence of conventional risk factors for ischaemic heart disease in patients with peripheral vascular disease, and the scope for preventative treatment with lipid-lowering therapy in this group, by retrospectively reviewing 299 patients who had undergone peripheral angiography in 1996. A total of 278 patients had severe peripheral vascular disease; 44% were current smokers at the time of their angiogram, and 36% had a history of coronary artery disease (either myocardial infarction, coronary artery bypass surgery, coronary angioplasty or angina). Cholesterol had been measured in 80 (27%) patients, of whom 26 (9%) were receiving treatment for hypercholesterolaemia. Patients with a history of ischaemic heart disease were more likely to have had their cholesterol measured (50% vs. 15%; p < 0.001). Hypertension (defined as systolic > 160 mmHg or diastolic > 90 mmHg) was present in 44%. There was no difference in the distribution of risk factors between those with and those without known ischaemic heart disease. There is a high prevalence of modifiable risk factors for coronary disease in patients with severe peripheral vascular disease. Effective prevention is available for coronary artery disease, but we found low levels of treatment. There is considerable scope for intervention to reduce the risk of coronary disease in such patients.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10396610     DOI: 10.1093/qjmed/92.4.219

Source DB:  PubMed          Journal:  QJM        ISSN: 1460-2393


  5 in total

1.  Incidence of and factors associated with achieving target lipid levels in patients with peripheral arterial disease.

Authors:  Meggan R Banta; Fangchao Ma; Dawn M Bravata; Robert S Kirsner; Daniel G Federman
Journal:  J Gen Intern Med       Date:  2006-07       Impact factor: 5.128

2.  Atherosclerotic risk factor reduction in peripheral arterial diseasea: results of a national physician survey.

Authors:  Mary McGrae McDermott; Elizabeth A Hahn; Philip Greenland; David Cella; Judith K Ockene; Donna Brogan; William H Pearce; Alan T Hirsch; Kendra Hanley; Linda Odom; Shaheen Khan; Michael H Criqui; Martin S Lipsky; Stacie Hudgens
Journal:  J Gen Intern Med       Date:  2002-12       Impact factor: 5.128

Review 3.  Current therapies and investigational drugs for peripheral arterial disease.

Authors:  Jun-Ichi Suzuki; Munehisa Shimamura; Hiroyuki Suda; Kouji Wakayama; Hidetoshi Kumagai; Yuichi Ikeda; Hiroshi Akazawa; Mitsuaki Isobe; Issei Komuro; Ryuichi Morishita
Journal:  Hypertens Res       Date:  2015-12-03       Impact factor: 3.872

4.  Aspirin nonsensitivity in patients with vascular disease: Assessment by light transmission aggregometry (aspirin nonsensitivity in vascular patients).

Authors:  Hamzah Khan; Abdelrahman Zamzam; Reid C Gallant; Muzammil H Syed; Margaret L Rand; Heyu Ni; Thomas L Forbes; Mohammed Al-Omran; Mohammad Qadura
Journal:  Res Pract Thromb Haemost       Date:  2021-11-16

5.  Elevated plasma levels of NT-proBNP in ambulatory patients with peripheral arterial disease.

Authors:  Bader Alsuwailem; Abdelrahman Zamzam; Muzammil H Syed; Elisa Greco; Mark Wheatcroft; Charles de Mestral; Mohammed Al-Omran; John Harlock; John Eikelboom; Krishna K Singh; Rawand Abdin; Mohammad Qadura
Journal:  PLoS One       Date:  2021-07-21       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.